Tag Archives: Ethics approval

CannPal Receives Ethics Approvals for Phase 1B Study in Dogs

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce it has received ethics approval to advance its clinical development plans for CPAT-01, a pain control being developed for cats and dogs. Key Highlights CannPal has received ethics approvals to advance the development of its lead drug candidate, CPAT-01, a pain … Continue reading

August 2, 2018 Latest News, News

CannPal Receives Ethics Approval for the Commencement of Clinical Trial in Dogs

Key Highlights Ethics approval received for large pharmacokinetic and safety study in dogs CannPal’s lead drug candidate, CPAT-01, is being developed as a pain medication for companion animals The trial subjects will be evaluated for safety, tolerability and clinical observations using both psychoactive (THC) and non-psychoactive (CBD) cannabis compounds Over 48 dogs will be evaluated … Continue reading

October 25, 2017 Latest News, News